Regeneron Pharmaceuticals Under Investigation for Alleged Violations
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is currently the subject of a significant investigation spearheaded by the Law Offices of Howard G. Smith. This inquiry focuses on potential violations of federal securities laws that may have serious implications for investors.
Details of the Investigation
Recently, the U.S. Department of Justice (DOJ) took action against Regeneron. The DOJ's announcement mentioned a lawsuit filed against the company under the False Claims Act. This legal move alleges that Regeneron inflated Medicare reimbursement rates for its drug Eylea. The complaint asserts that Regeneron knowingly submitted false reports to the Centers for Medicare and Medicaid Services, thereby excluding certain price concessions.
As noted in official statements, these actions purportedly led to a substantial increase in the drug's costs to Medicare, significantly boosting Regeneron’s revenue over the years. Such allegations, if proven, raise serious concerns about the company's operational integrity.
Impact on Stock Price
The announcement had immediate repercussions on Regeneron’s stock. Following the news, shares plunged by $31.50, equating to a 3.4% drop, to close at $904.70 per share by April 12, 2024. This downturn represents a significant loss for investors in just a couple of trading days.
Subsequent Financial Results
As the situation unfolded, Regeneron disclosed its third-quarter financial results for 2024 on October 31. The company reported that U.S. net sales for its flagship products, EYLEA HD® and EYLEA®, rose by 3% compared to the previous year, totaling $1.54 billion, which included $392 million from EYLEA HD.
However, amidst this seemingly positive news, Regeneron also acknowledged that the net product sales for EYLEA were adversely affected by a lower selling price in comparison to the same quarter in the previous year. Consequently, media reports highlighted that the company had underperformed expectations regarding quarterly sales from its higher-dose Eylea variant.
As a result of these disclosures, Regeneron's stock price experienced a further decline. On the same day of the earnings release, stocks fell by $84.59, representing a 9.2% decrease, and closing at $838.20 per share. Such fluctuations indicate ongoing investor concern regarding the company's future following these events.
What You Can Do
If you have investments in Regeneron and are concerned about how these developments could affect your financial standing, it is crucial to seek advice promptly. Getting involved in the investigation could help protect your rights as an investor.
For those with knowledge pertinent to these claims, or if you seek further information about your rights concerning the situation, reaching out to the Law Offices of Howard G. Smith may be beneficial. Individuals can connect directly with Howard G. Smith at their office, located at 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania, or via telephone.
Frequently Asked Questions
What allegations has Regeneron Pharmaceuticals faced?
Regeneron is currently facing allegations from the U.S. Department of Justice regarding fraudulent Medicare reimbursement practices for their drug Eylea.
How did Regeneron's stock react to the recent news?
Following the DOJ announcement, Regeneron's stock price fell by $31.50 and then dropped another $84.59 after disappointing financial results.
What are the potential implications for investors?
If the allegations are proven true, investors could face significant financial losses, and they are encouraged to seek legal advice.
Who can I contact for more information regarding my rights?
Investors can reach out to Howard G. Smith at the Law Offices of Howard G. Smith for inquiries related to their rights and interests.
Can investors join the ongoing investigation?
Yes, investors with relevant information can participate in the investigation being handled by the Law Offices of Howard G. Smith.
